Literature DB >> 15651754

Virological effects of ISIS 14803, an antisense oligonucleotide inhibitor of hepatitis C virus (HCV) internal ribosome entry site (IRES), on HCV IRES in chronic hepatitis C patients and examination of the potential role of primary and secondary HCV resistance in the outcome of treatment.

Muriel Soler1, John G McHutchison, T Jesse Kwoh, F Andrew Dorr, Jean-Michel Pawlotsky.   

Abstract

Antisense oligonucleotides represent a promising class of antiviral agents. ISIS 14803 is a 20-unit phosphorothioate oligodeoxynucleotide that inhibited hepatitis C virus (HCV) replication and protein expression in cell culture and mouse models. A Phase I dose-escalation clinical study of ISIS 14803 was performed in 24 patients with HCV genotype 1 chronic hepatitis C. The patients received 0.5, 1.0, 2.0 or 3.0 mg/kg of ISIS 14803 for 4 weeks. Two of them receiving 2.0 mg/kg, experienced a significant (>1.0 log10) viral load reduction and nine other patients experienced minor (<1.0 log10) viral load reductions that were difficult to definitively distinguish from assay or patient variations. The aims of this study were to examine the effect of ISIS 14803 on its target site and neighbouring region quasispecies evolution, and to determine whether primary and secondary HCV resistance contributed to the observed virological response rate. The HCV internal ribosome entry site (IRES), including the ISIS 14803 target site in virus specimens collected from patients at baseline and end-of-treatment, was sequenced. An extensive IRES quasispecies analysis was performed in 10 of the patients at various time points before, during and after ISIS 14803 treatment. A significant IRES genetic evolution was found in three out of 10 patients through quasispecies analysis suggesting that treatment with ISIS 14803, a drug designed to bind to HCV RNA, exerted a selective pressure on HCV IRES. However, no mutations in the ISIS 14803 target site, which would inhibit binding of the oligonucleotide to HCV RNA, were detected before (primary resistance) or after treatment (secondary resistance) with the oligonucleotide. Furthermore, no obvious nucleotide changes in the surrounding IRES region that might possibly affect oligonucleotide binding were detected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15651754

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  7 in total

1.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.

Authors:  Ivan A Andreev; Dinesh Manvar; Maria Letizia Barreca; Dmitry S Belov; Amartya Basu; Noreena L Sweeney; Nina K Ratmanova; Evgeny R Lukyanenko; Giuseppe Manfroni; Violetta Cecchetti; David N Frick; Andrea Altieri; Neerja Kaushik-Basu; Alexander V Kurkin
Journal:  Eur J Med Chem       Date:  2015-04-10       Impact factor: 6.514

3.  Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site.

Authors:  Carl Laxton; Kevin Brady; Sterghios Moschos; Paul Turnpenny; Jaiessh Rawal; David C Pryde; Ben Sidders; Romu Corbau; Chris Pickford; E J Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

Review 4.  Hepatitis C virus translation inhibitors targeting the internal ribosomal entry site.

Authors:  Sergey M Dibrov; Jerod Parsons; Maia Carnevali; Shu Zhou; Kevin D Rynearson; Kejia Ding; Emily Garcia Sega; Nicholas D Brunn; Mark A Boerneke; Maria P Castaldi; Thomas Hermann
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

Review 5.  Prospects for nucleic acid-based therapeutics against hepatitis C virus.

Authors:  Chang Ho Lee; Ji Hyun Kim; Seong-Wook Lee
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 6.  Unconventional viral gene expression mechanisms as therapeutic targets.

Authors:  Jessica Sook Yuin Ho; Zeyu Zhu; Ivan Marazzi
Journal:  Nature       Date:  2021-05-19       Impact factor: 49.962

7.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.